Biogen hepatitis B patents
Abbott joins list of firms licensing Biogen's hepatitis B patents. Royalty-bearing license covers manufacture, use and sale of hepatitis B core antigens in diagnostic kits. Biogen estimates that its hepatitis B licensing program, which includes SmithKline licensure for its hepatitis B vaccine, could yield $ 10 mil. a year in product-driven revenues. A separate patent for hepatitis B surface antigen produced from genetically engineered yeast, which covers Merck's Recombivax HB vaccine, was granted Sept. 6 to inventors of the vaccine at the University of California ("The Pink Sheet" Sept. 12, "In Brief").
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?